BAIN GLOBAL RESOURCES PTY LTD
Location
WESTERN AUSTRALIA
Founded
2022-12-17
Website
Risk Signals
655 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Metal Mining Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about BAIN GLOBAL RESOURCES PTY LTD
Live alerts from global media, monitored by Business Radar
2025-05-18 (bloomberglinea.com)
Credit card market is the new bid stage between banks and Fintechs
The placement of credit cards should not only be measured by the plastics issued, but also for their relationship with customers.
Read more
2025-05-06 (the-drawdown.com)
Looking for liquidity: continuation funds and NAV loans to the rescue | The DRAWDºWN
In tepid exit markets where sponsors have been under pressure to find creative ways to return capital to investors and LPs, GP-led continuation funds and NAV loans have provided welcome alternative pathways to liquidity
Read more
2025-05-06 (finyear.com)
Study | Stablecoins: From niche to standard, a revolution in financial payments -
At a time when Stablecoins have hundreds of billions of dollars in American treasury vouchers, their transition to massive use in the global financial system seems inevitable. Bain & Company deciphers this rise in power and its implications for companies, banks and consumers. A dazzling climb: the stablecoins <a href = "https://finyear.com/etude-stablecoins-de-la-niche-a-la-norme-une-nevolution-dans-s-s-s-paiements-financers/" Class = "More-Link"> ... <span class = "Screen-reader-text"> Study | Stablecoins: From niche to standard, a revolution in financial payments </ span> </a>
Read more
2025-04-02 (fiercebiotech.com)
Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow
Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech's gene therapy designed to reverse or prevent blindness through | Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech's gene therapy designed to reverse or prevent blindness through a potential market approval.
Read more
2022-08-02 (fiercehealthcare.com)
Retailers, payers and startups could capture 30% of primary care market by 2030: report
Primary care has become a hot market as U.S. retailers place big bets on healthcare and payers and startups like Oak Street Health see a sector that's ripe for disruption. | Bringing new care and reimbursement models to the market along with a bigger focus on virtual care, nontraditional players have the potential to grab as much as a third of the U.S. primary care market by 2030, according to a new report from Bain and Company.
Read more
2022-05-10 (buyoutsinsider.com)
Albaron Partners, with Blackstone, Bain pedigree, readies debut fund for untapped healthcare
Albaron is among a crop of first-timers braving the tough fundraising market to try to attract capital from picky LPs.
Read more